Renaissance Technologies LLC reduced its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) by 10.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 865,354 shares of the company’s stock after selling 102,492 shares during the period. Renaissance Technologies LLC owned approximately 0.67% of Compass Pathways worth $4,785,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in CMPS. RTW Investments LP raised its stake in shares of Compass Pathways by 0.6% during the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock valued at $60,426,000 after purchasing an additional 50,000 shares during the period. Nantahala Capital Management LLC boosted its stake in Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the period. Millennium Management LLC grew its holdings in Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after buying an additional 774,090 shares in the last quarter. Toronto Dominion Bank grew its holdings in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after buying an additional 1,529,013 shares in the last quarter. Finally, ARK Investment Management LLC increased its position in shares of Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock valued at $14,876,000 after buying an additional 34,894 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.
Compass Pathways News Summary
Here are the key news stories impacting Compass Pathways this week:
- Positive Sentiment: B. Riley raised its price target from $17 to $22 and assigned a “Buy” rating. The new target implies approximately 62% upside from the referenced share price, signaling increased confidence in Compass Pathways’ pipeline and the potential commercial opportunity for COMP360. Benzinga article
- Positive Sentiment: Management described the first half of 2026 as a defining period, citing continued momentum across clinical, regulatory and commercial activities as it prepares for the potential approval and launch of COMP360, its investigational mental-health treatment. Compass Pathways second-quarter results and business highlights
- Neutral Sentiment: Compass Pathways will participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12. The presentation could provide updates on clinical development, regulatory plans and financing, but no new information was reported yet. Canaccord Genuity conference announcement
- Negative Sentiment: The company reported a second-quarter loss of $1.88 per share, missing the consensus estimate of a $0.39 loss by $1.49. Coverage also highlighted a wider year-over-year loss and higher operating expenses, which could increase concerns about cash burn even as Compass advances its development programs. Compass Pathways shares rise amid wider second-quarter loss
Analysts Set New Price Targets
Read Our Latest Analysis on CMPS
Compass Pathways Stock Performance
Shares of CMPS opened at $13.55 on Friday. The company has a market cap of $1.83 billion, a PE ratio of -2.93 and a beta of 2.50. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average price of $12.58 and a 200-day moving average price of $9.31. Compass Pathways PLC Sponsored ADR has a 12-month low of $3.97 and a 12-month high of $15.40.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, equities analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.
About Compass Pathways
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
Featured Articles
- Five stocks we like better than Compass Pathways
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report).
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
